RxDoctor Payments Data

Kimberly Barbolla, DO

Internal Medicine · Marshall, TXNPI 1437132081

Payments from drug & device makers

$8,938in general payments, 2019–2025

Across 591 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$923
  • Bayer$892
  • Lilly USA, LLC$826
  • AbbVie$809
  • Amgen$741
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,924100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,938 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$313,126
Medicare patients
289
Services billed
1,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin330$205,116
OzempicSemaglutide105$122,200
EliquisApixaban132$84,462
FarxigaDapagliflozin Propanediol96$75,676
MounjaroTirzepatide62$71,246
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$57,948
KerendiaFinerenone66$55,291
XareltoRivaroxaban65$51,303
LinzessLinaclotide53$44,610
MyrbetriqMirabegron131$39,608
XifaxanRifaximin24$37,886
JanuviaSitagliptin Phosphate59$34,964
RybelsusSemaglutide16$30,855
ProliaDenosumab12$21,043
CaplytaLumateperone Tosylate23$19,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$181$205,116330 claims
Novo NordiskOzempic, Rybelsus$1,005$153,055121 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$923$96,924143 claims
PfizerEliquis$411$84,462132 claims
Lilly USA, LLCMounjaro$826$71,24662 claims
GSKTrelegy Ellipta, Anoro Ellipta$160$69,02167 claims
BayerKerendia$892$55,29166 claims
Johnson & JohnsonXarelto$138$51,30365 claims
AbbVieLinzess$809$44,61053 claims
Astellas Pharma US IncMyrbetriq$16$39,608131 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$277$37,88624 claims
MerckJanuvia$84$34,96459 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Marshall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →